Introduction
The high-molecular-weight polyethylenimine (PEI) has not been clinically used because of its nonspecific cytotoxicity displayed against different cell types. 1 On the other hand, low-molecular-weight PEIs are much less cytotoxic, but they are not efficient transfection agents because of limitations of DNA delivery into the cytoplasm. 2 Hence, the hydrophobic modification of low-molecular-weight PEI 2 kDa (PEI2) by cholic acid (ChA) was performed as previously reported 3 to form PEI2-ChA, and in vitro and in vivo studies were performed.
Materials and methods Materials
PEI2 was purchased from Sigma-Aldrich (St Louis, MO, USA). Plasmid p53 (p53-expressing plasmid) was a generous gift from Dr Bert Vogelstein Lab, Johns Hopkins University (Baltimore, MD, USA). Plasmid gWIZ-GFP (GFP-expressing reporter plasmid) was obtained from Aldevron (Fargo, Canada). Primary antibody p53 (F-8; # sc-374087) and secondary antibody IgG-HRP (# sc-2005) were obtained from Santa Cruz Biotechnology (New Delhi, India). Animal imaging was carried out using IVIS Lumina II (Caliper Life Sciences, Cheshire, UK). The NT8e cells were used as available (isolated and developed in Dr Rita Mulherkar's Genetic Engineering Laboratory at Advanced Centre for Treatment, Research and Education in Cancer [ACTREC], Kharghar, Mumbai, India).
Methods
The NT8e cells were transfected with nanoplexes (polymer:pDNA weight ratio of 10) 
84
Dube et al microscopy. For in vitro protein expression studies, the NT8e cells were transfected with 60 µL of nanoplexes containing 3.6 µg of gWIZ-GFP, and GFP expression was evaluated by Western blotting. 5 Biodistribution of nanoplexes was evaluated by injecting animals with 100 µL of either pDNA in saline or nanoplexes without transferrin or nanoplexes incorporated with transferrin through tail vein of Swiss bare mice. For tumor regression studies, animals were treated with 8 µg of plasmid p53 in transferrin-containing PEI2-ChA nanoplexes and evaluated for tumor volume after 48 days of treatment. 6 
Results and discussion
The nanoplexes of PEI2-ChA with gWIZ-GFP were shown to increase the transfection efficiency (~27%) in NT8e cell lines (Figure 1 ) as evaluated by flow cytometry and also observed from fluorescence images (Figure 2) . The cell cycle analysis of NT8e cells (p53 mutant) treated with transferrincontaining nanoplexes of PEI2-ChA with plasmid p53 showed increased apoptosis of cells, which appeared to be due to restored p53 function. In vitro protein expression study using Western blot analysis revealed the expression of exogenous p53 protein (Figure 3) . In vivo imaging of mice treated with nanoplexes of PEI2-ChA-containing transferrin demonstrated localized signal for GFP protein in the brain region. Tumor regression is an improvement or cure from a disease that appears to be progressing in its severity. Thus, based on the results obtained in the present research work, it can be concluded that the transferrin-containing nanoplexes of PEI2-ChA conjugates with plasmid p53 warrant clinical trials in humans after exhaustive animal studies for use as a novel gene delivery system.
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